Golden State Wealth Management LLC Acquires New Holdings in Danaher Co. (NYSE:DHR)

Golden State Wealth Management LLC acquired a new stake in shares of Danaher Co. (NYSE:DHR) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 134 shares of the conglomerate’s stock, valued at approximately $31,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC raised its position in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after acquiring an additional 148,251 shares in the last quarter. Fisher Asset Management LLC raised its position in Danaher by 2.6% in the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after acquiring an additional 116,299 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after acquiring an additional 535,254 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. raised its position in Danaher by 0.6% in the fourth quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock worth $382,936,000 after acquiring an additional 9,942 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Down 1.2 %

Shares of Danaher stock opened at $201.15 on Wednesday. The stock has a market capitalization of $145.29 billion, a P/E ratio of 38.10, a PEG ratio of 2.68 and a beta of 0.83. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The stock has a 50 day moving average price of $231.96 and a two-hundred day moving average price of $251.14. Danaher Co. has a 12-month low of $199.75 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the firm earned $2.09 earnings per share. Equities analysts expect that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.54%. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Wall Street Analyst Weigh In

Several brokerages have commented on DHR. KeyCorp boosted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Stifel Nicolaus boosted their price objective on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird cut their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. JPMorgan Chase & Co. cut their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Finally, Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.